Literature DB >> 18061169

Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease.

Melissa K McCoy1, Terina N Martinez, Kelly A Ruhn, Philip C Wrage, Edward W Keefer, Barry R Botterman, Keith E Tansey, Malú G Tansey.   

Abstract

Adult adipose contains stromal progenitor cells with neurogenic potential. However, the stability of neuronal phenotypes adopted by Adipose-Derived Adult Stromal (ADAS) cells and whether terminal neuronal differentiation is required for their consideration as alternatives in cell replacement strategies to treat neurological disorders is largely unknown. We investigated whether in vitro neural induction of ADAS cells determined their ability to neuroprotect or restore function in a lesioned dopaminergic pathway. In vitro-expanded naïve or differentiated ADAS cells were autologously transplanted into substantia nigra 1 week after an intrastriatal 6-hydroxydopamine injection. Neurochemical and behavioral measures demonstrated neuroprotective effects of both ADAS grafts against 6-hydroxydopamine-induced dopaminergic neuron death, suggesting that pre-transplantation differentiation of the cells does not determine their ability to survive or neuroprotect in vivo. Therefore, we investigated whether equivalent protection by naïve and neurally-induced ADAS grafts resulted from robust in situ differentiation of both graft types into dopaminergic fates. Immunohistological analyses revealed that ADAS cells did not adopt dopaminergic cell fates in situ, consistent with the limited ability of these cells to undergo terminal differentiation into electrically active neurons in vitro. Moreover, re-exposure of neurally-differentiated ADAS cells to serum-containing medium in vitro confirmed ADAS cell phenotypic instability (plasticity). Lastly, given that gene expression analyses of in vitro-expanded ADAS cells revealed that both naïve and differentiated ADAS cells express potent dopaminergic survival factors, ADAS transplants may have exerted neuroprotective effects by production of trophic factors at the lesion site. ADAS cells may be ideal for ex vivo gene transfer therapies in Parkinson's disease treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061169      PMCID: PMC2394500          DOI: 10.1016/j.expneurol.2007.10.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  80 in total

Review 1.  Stem cell plasticity.

Authors:  Uma Lakshmipathy; Catherine Verfaillie
Journal:  Blood Rev       Date:  2005-01       Impact factor: 8.250

2.  A dermal niche for multipotent adult skin-derived precursor cells.

Authors:  Karl J L Fernandes; Ian A McKenzie; Pleasantine Mill; Kristen M Smith; Mahnaz Akhavan; Fanie Barnabé-Heider; Jeff Biernaskie; Adrienne Junek; Nao R Kobayashi; Jean G Toma; David R Kaplan; Patricia A Labosky; Victor Rafuse; Chi-Chung Hui; Freda D Miller
Journal:  Nat Cell Biol       Date:  2004-11       Impact factor: 28.824

3.  Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator.

Authors:  M J West; L Slomianka; H J Gundersen
Journal:  Anat Rec       Date:  1991-12

Review 4.  Hepatic stem cells.

Authors:  M Alison; C Sarraf
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

5.  Analysis of mitochondrial morphology and function with novel fixable fluorescent stains.

Authors:  M Poot; Y Z Zhang; J A Krämer; K S Wells; L J Jones; D K Hanzel; A G Lugade; V L Singer; R P Haugland
Journal:  J Histochem Cytochem       Date:  1996-12       Impact factor: 2.479

Review 6.  Isolation, characterization, and use of stem cells from the CNS.

Authors:  F H Gage; J Ray; L J Fisher
Journal:  Annu Rev Neurosci       Date:  1995       Impact factor: 12.449

7.  Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat.

Authors:  D C German; K F Manaye
Journal:  J Comp Neurol       Date:  1993-05-15       Impact factor: 3.215

8.  Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells.

Authors:  Jenny Hsieh; Kinichi Nakashima; Tomoko Kuwabara; Eunice Mejia; Fred H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-10       Impact factor: 11.205

9.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

Authors:  L F Lin; D H Doherty; J D Lile; S Bektesh; F Collins
Journal:  Science       Date:  1993-05-21       Impact factor: 47.728

10.  Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  M Levivier; S Przedborski; C Bencsics; U J Kang
Journal:  J Neurosci       Date:  1995-12       Impact factor: 6.167

View more
  29 in total

Review 1.  Biological functions of mesenchymal stem cells and clinical implications.

Authors:  Abderrahim Naji; Masamitsu Eitoku; Benoit Favier; Frédéric Deschaseaux; Nathalie Rouas-Freiss; Narufumi Suganuma
Journal:  Cell Mol Life Sci       Date:  2019-05-04       Impact factor: 9.261

2.  Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons.

Authors:  Juan Andrés Parga; María García-Garrote; Salvador Martínez; Ángel Raya; José Luis Labandeira-García; Jannette Rodríguez-Pallares
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

Review 3.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

Review 4.  Stem cell-based therapy as a promising approach in Alzheimer's disease: current perspectives on novel treatment.

Authors:  Saeid Bagheri-Mohammadi
Journal:  Cell Tissue Bank       Date:  2021-01-04       Impact factor: 1.522

Review 5.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 6.  Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

Authors:  Fábio G Teixeira; Miguel M Carvalho; Nuno Sousa; António J Salgado
Journal:  Cell Mol Life Sci       Date:  2013-03-01       Impact factor: 9.261

Review 7.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 8.  Preclinical assessment of stem cell therapies for neurological diseases.

Authors:  Valerie L Joers; Marina E Emborg
Journal:  ILAR J       Date:  2009

9.  Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells.

Authors:  Xi Chen; Jianjun Chang; Qiudong Deng; Jie Xu; Thi A Nguyen; Lauren H Martens; Basar Cenik; Georgia Taylor; Kathryn F Hudson; Jaegwon Chung; Kimberley Yu; Phillip Yu; Joachim Herz; Robert V Farese; Thomas Kukar; Malú G Tansey
Journal:  J Neurosci       Date:  2013-05-22       Impact factor: 6.167

10.  Human adipose tissue-derived multilineage progenitor cells exposed to oxidative stress induce neurite outgrowth in PC12 cells through p38 MAPK signaling.

Authors:  Mariko Moriyama; Hiroyuki Moriyama; Ayaka Ueda; Yusuke Nishibata; Hanayuki Okura; Akihiro Ichinose; Akifumi Matsuyama; Takao Hayakawa
Journal:  BMC Cell Biol       Date:  2012-08-07       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.